Reports Q4 revenue $954M, consensus $936.68M. “IDEXX had a solid finish to 2024, supported by continued high levels of execution by IDEXX teams globally,” said CEO Jay Mazelsky. “The Company is on the front end of a new wave of major innovation. In Q4, we began shipping the IDEXX inVue Dx Cellular Analyzer, our transformational slide-free cellular analyzer, and we plan to make IDEXX Cancer Dx screening for canine lymphoma available in late March 2025 in the U.S. and Canada. These types of innovations are highly sought-after by our customers and will dramatically enhance veterinarians’ approaches to care management and address workflow bottlenecks in their practices.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- IDXX Upcoming Earnings Report: What to Expect?
- Idexx Laboratories price target lowered to $550 from $559 at Morgan Stanley
- Zoetis price target lowered to $180 from $210 at Stifel
- Idexx Laboratories Approves Nonqualified Deferred Compensation Plan
- Idexx Laboratories announces 5M share increase in share repurchase pact